A recent study suggests that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end traditional diet and exercise plans.
Published data in a major health publication shows that while obese people often shed about a fifth of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing these medications must be informed of the potential of rapid weight regain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
This pace of regain suggests a reversion to starting weight in about one and a half years.
Analyzing Approaches
The research, which reviewed 37 of studies involving thousands of participants, contrasted the results of these new drugs with older methods.
The team emphasize that individuals who lose weight through dieting usually have a more gradual creep back—approximately 0.1 kg a month—once they finish.
Understanding the Quick Regain
Doctors believe the mechanism of the drugs is key to understanding the heightened rebound.
The injections mimic a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement means appetite is no longer kept in check, making binge eating a significant risk."
A Lifelong Condition?
Health authorities suggest the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, considering the likelihood of weight regain, the therapy is often life-long.
This view is reinforced by pharmaceutical companies, who state that the results "highlight the chronic nature of obesity," akin to managing conditions like hypertension.
Patient Accounts
Users who have come off the medication describe a powerful resurgence of cravings.
"It felt as if a switch that goes on and I was suddenly ravenous," described an individual.
This challenge is exacerbated if users have not adopted permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Figures indicate that millions of people in the UK have used these injections in the past year, with desire remaining high.
- Adoption is higher among women than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic fix and lasting health benefits likely depends on combined lifestyle changes.